Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

 
• By Joseph Haas

Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.

Cancer
Amgen thinks Five Prime's bemarituzumab offers utility in various tumor types

More from Deals

More from Business